However, a previous study has shown that romo1 is a poor prognostic factor in advanced NSCLC [15]; additional patient data analyzed according to stage may further support its use as a prognostic indicator in advanced NSCLC. This evidence concerns the gene ROMO1 and non-small cell lung carcinoma.